Frequency and Risk Factors of Red Blood Cell Alloimmunization in Thalassemia Major Patients in Markazi province

Authors

  • Aziz Eghbali Associate Professor, Department of Pediatrics Hematologys and Oncology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
  • Roghaieh Rahimi afzal . Pediatric resident, Department of Pediatrics Hematology and Oncology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
  • Sarvenaz Mehrabi General Practitionar, Department of emergency, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
  • Seyedamir Sanatkar General Practitionar, Department of Surgery, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Abstract:

Background: Thalassemia is one of the most common genetic disorders throughout the world. Blood transfusion plays an important role in the treatment of thalassemia but it leads to numerous complications such as iron overload and alloimmunization. This study evaluated the frequency and risk factors associated with alloimmunization in thalassemia major patients living in Markazi province, Iran. Materials and Methods: In this descriptive study, 48 thalassemia major patients who underwent blood transfusion at Amirkabir hospital were included. Patients' demographic data were recorded using a questionnaire. In order to perform alloimmunization screening and autoantibody assessment, patients were referred to Tehran Blood Transfusion Organization Laboratory. Results: The current study was performed on 48 patients with thalassemia major,. The mean age of patients was 12.5 ± 8.3 years. Among patients 26 (54.16%) were male and 22 (45.83%) were female, 13 patients (27.08%) had alloantibodies. Among 48 patients, 19 (39.58%) had undergone splenectomy. The patients' age of the first blood transfusion ranged from 1 month to 14 months      and the mean age of the first blood transfusion was 9.5 ± 7.08 months. The blood transfusion intervals in patients were from 21 days to 40 days and the blood volume received at each transfusion session was 10-15 cc/kg of the body weight. In the current study, the data analysis indicated no significant correlation between alloantibodies and RH phenotype (P=0.43), patients' gender (P=0.9), or blood groups (P=0.4); whereas, a significant correlation was found between alloantibodies and splenectomy (P=0.02) as an increase in the prevalence of alloantibodies was reported in splenectomised patients. Conclusion: No significant difference was found between the patients with and without alloantibodies in terms of the prevalence of Rh phenotype, gender, and blood groups. However, there was a significant difference between the patients with and without alloantibodies in terms of splenectomy.  

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Red Blood Cell Alloimmunization in Patients with Thalassemia Major and Intermediate in Southwest Iran

Background: Transfusion is the mainstay treatment of patients with thalassemia major and occasionally in thalassemia intermediate. Alloimmunization is an unwanted side effect of blood transfusion. The present study intended to determine the frequency of alloimmunization in patients with β- thalassemia major and thalassemia intermediate in Southwest Iran. Patients and Methods: This was a cross-...

full text

red blood cell alloimmunization in patients with thalassemia major and intermediate in southwest iran

background: transfusion is the mainstay treatment of patients with thalassemia major and occasionally in thalassemia intermediate. alloimmunization is an unwanted side effect of blood transfusion. the present study intended to determine the frequency of alloimmunization in patients with β- thalassemia major and thalassemia intermediate in southwest iran. patients and methods: this was a cross-s...

full text

Red Blood Cells Alloimmunization and Autoimmunization in Multi-transfused Thalassemia Patients in South of Iran

Background: Recurrent blood transfusion is a common treatment in patients with thalassemia. The development of antibodies against red blood cell (RBC) antigens complicates RBC cross-matching, enhances the in vivo destruction of transfused cells, accelerates tissue iron overloading, delays the provision of safe transfusion, and reduces health-related quality of life. Materials and Methods: In t...

full text

Frequency of Red Cell Alloimmunization and Autoimmunization in Thalassemia Patients: A Report from Eastern India

Introduction. Red blood cell (RBC) alloimmunization and autoimmunization remain a major problem in transfusion dependent thalassemic patients. There is a paucity of data on the incidence of RBC alloimmunization and autoimmunization in thalassemic patients from eastern part of India, as pretransfusion antibody screening is not routinely performed. Aims. To assess the incidence of RBC alloimmuniz...

full text

Prevalence and Risk Factors of Pulmonary Arterial Hypertension in Thalassemia Major Patients of Ilam, 2014

Pulmonary arterial hypertension (PAH) is a progressive disease with high morbidity and mortality rates. Research has shown that PAH has a prevalence rate of 10-79% in thalassemia major patients. This cross-sectional study was carried out in 2014 to determine the prevalence and risk factors of PAH in all thalassemia major patients of over 18 years of age in Ilam, Iran. A cardiologist measured sy...

full text

Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.

Red blood cell transfusions have reduced morbidity and mortality for patients with sickle cell disease. Transfusions can lead to erythrocyte alloimmunization, however, with serious complications for the patient including life-threatening delayed hemolytic transfusion reactions and difficulty in finding compatible units, which can cause transfusion delays. In this review, we discuss the risk fac...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 9  issue 1

pages  25- 31

publication date 2019-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023